The Rising Trend of Protein: A Focus on GLP-1 Medications

Protein is gaining unprecedented popularity, and the trend surrounding GLP-1 medications is amplifying this interest. Companies are competing to develop more soluble and digestible protein options, enabling brands to incorporate higher protein content into innovative products ranging from protein water to drinkable yogurt.

The Importance of Protein amid Weight Loss

Prolonged muscle loss is a salient concern for individuals rapidly losing weight on GLP-1 medications. While adequate protein intake is crucial, experts argue that our obsession with protein might be misplaced. Renowned nutritionist Dr. Ryan Kane of the Food is Medicine Institute at Tufts University emphasizes that merely increasing protein without accompanying resistance exercises might not yield the expected benefits.

The Role of Resistance Exercise

“The excitement around GLP-1 drugs often overlooks the importance of resistance training,” Dr. Kane stated during a recent panel discussion hosted by AgFunderNews. He remarked, “While it’s important to ensure adequate protein intake, if resistance activities aren’t incorporated, the excess protein can just convert to fat due to surplus calories.”

Nutritional Gaps Beyond Protein

Dr. Kane highlighted that nutritional deficiencies extend beyond protein consumption. The latest dietary guidelines for Americans indicate that Americans typically consume sufficient protein; however, there are notable gaps in fiber, minimally processed foods, fruits, vegetables, and healthy fats.

GLP-1s and Their Future Impact on the Food Industry

A Kaiser Family Foundation survey in 2024 revealed that 6% of U.S. adults are currently using GLP-1 drugs, with 12% having tried them. Should accessibility and affordability improve, the implications for the food industry could be profound.

Potential Industry Transformations

Could a significant portion of the population using these medications lead to a decline in junk food consumption and a rise in fresh produce sales? Or will it simply provide an avenue for major food corporations to introduce more processed options? This dilemma leads to critical questions about the industry’s future.

The Expert Panel Discussion

Recently, AgFunder assembled a panel of industry experts to discuss the potential impacts of GLP-1s:

• Ryan Kane, Assistant Professor at the Food is Medicine Institute at Tufts University
• Nick Fereday, Independent Advisor and Speaker
• Steven Finn, Managing Partner at Siddhi Capital
• Zohar Barbash, Co-founder of Lembas
• Devon Gholam, VP of Science and Innovation at Step Change Innovations

Key Discussion Points

• Future product formats and tolerability of new agonist treatments.
• Long-term efficacy and usage patterns—will these medications resemble statins?
• Concerns about metabolic impacts of intermittent use.
• Recommended wrap-around support systems for users.
• Predicted changes in food and supplement aisles and restaurant menus.
• Behavioral shifts in eating and shopping habits due to GLP-1 medications.
• Potential for new food and supplement innovations inspired by drug mechanisms.
• Investment opportunities in food tech centered around these diets.
• Industry responses—fear, opportunity, or both?

Further Reading

To explore this evolving narrative, consider these resources:

• ‘GLP-1 drugs are a tool, not a panacea’
• ‘Evolv launches peptide targeting GLP-1 receptors’
• ‘Expect new wave of breakthroughs in food technology’

For a deeper dive, you can watch the full panel discussion here:

https://www.youtube.com/watch?v=ASQbOnNjNPY" width="100%" height="400